Firsts Home

Equity & Derivatives Companies, sectors, M&A and the financial industry
Vanda shares jump 8-fold as Reuters first with drug approval 05.06.2009 Shares of biotech company Vanda jumped nearly eight-fold on May 6 after Reuters was out front with news that the FDA had reversed course and approved its schizophrenia drug. The agency’s about-face shocked investors, who swooped in to buy the previously beleaguered stock. Reuters was more than an hour ahead of Dow Jones and more than a minute ahead of Bloomberg in sending out the first headlines. Reuters Firsts will need at least flash player 9 to give you the full experience. The latest Flash player can be downloaded here	firsts across any industry Commodities & Energy Energy, metals, agricultural and environmental markets FX & Money Markets Macroeconomics, monetary policy, FX and money markets Politics & Risk Politics and political risk Equity & Derivatives Companies, sectors, M&A and the financial industry Fixed Income Sovereign and corporate debt, credit, and ratings firsts by region Americas View stories from this region Europe / Middle East / Africa View stories from this region Asia View stories from this region Emerging Markets View stories from this region

Equity & Derivatives

Companies, sectors, M&A and the financial industry

Vanda shares jump 8-fold as Reuters first with drug approval

05.06.2009

Shares of biotech company Vanda jumped nearly eight-fold on May 6 after Reuters was out front with news that the FDA had reversed course and approved its schizophrenia drug. The agency’s about-face shocked investors, who swooped in to buy the previously beleaguered stock. Reuters was more than an hour ahead of Dow Jones and more than a minute ahead of Bloomberg in sending out the first headlines.

Reuters Firsts will need at least flash player 9 to give you the full experience. The latest Flash player can be downloaded here